Jason Ken Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason Ken Hou has a total of 230 co-authors. Here are the top co-authors by number of shared publications:
- Akbar K. Waljee
Center for Global Health Equity, Michigan Medicine, University of Michigan, Ann Arbor, Michigan, USA
11 shared publications Shubhada Sansgiry
VA Center for Innovations in Quality, Effectiveness, and Safety (IQuESt) , Michael E. DeBakey VA Medical Center, Houston, TX
8 shared publications- Hashem B. El-Serag
Department of Medicine, Baylor College of Medicine, Houston, TX, USA
7 shared publications - Jennifer R. Kramer
Department of Medicine Baylor College of Medicine Houston Texas USA
6 shared publications Peter Richardson
Michael E DeBakey VA Medical Center
6 shared publicationsLinda A. Feagins
5 shared publications
Latest Publications
- 2 February 2026
- Vol. 8 (1)
Treat-to-Target in Inflammatory Bowel Diseases: Lessons from Screening in a Pragmatic Clinical Trial
Treat-to-target (TTT) for patients with inflammatory bowel disease (IBD) involves treating to clinical and endoscopic remission. Despite control of clinical symptoms, many patients may not achieve endoscopic remission. Real-world prevalence and patient acceptance of staying on current advanced therapy vs switching in this scenario is not well defined. The aim of this study are to report real-world prevalence of symptomatic and endoscopic/radiologic discordance and patient and provider preferences regarding stay or switch advanced therapy in this setting. In the QUOTIENT trial, we performed screening exercises to estimate the prevalence of symptomatic and endoscopic/radiologic discordance using detailed screening logs for eligible patients. Sites completed screening exercises to identify what proportion of patients are eligible to participate in the QUOTIENT trial and willingness to participate. A total of 761 patients were screened for QUOTIENT with complete data. Of patients in corticosteroid-free symptomatic remission on an advanced therapy, 12% had moderate-to-severe endoscopic inflammation. The most common reason for declining to participate was patients’ preference to stay on current advanced therapy (39%). Only 11% preferred switching to advanced therapy as a reason to decline participation. Among patients with IBD who have achieved corticosteroid-free symptomatic remission on advanced therapies, real-world rates of achieving endoscopic remission or mild endoscopic activity are significantly higher than suggested by clinical trials. We observed a strong patient preference to stay on their current advanced therapy, rather than switching to an alternative agent, which contrasts with the providers’ framework for treat-to-target.
- 2 February 2026
- Vol. 8 (1)
Treat-to-Target in Inflammatory Bowel Diseases: Lessons from Screening in a Pragmatic Clinical Trial
Treat-to-target (TTT) for patients with inflammatory bowel disease (IBD) involves treating to clinical and endoscopic remission. Despite control of clinical symptoms, many patients may not achieve endoscopic remission. Real-world prevalence and patient acceptance of staying on current advanced therapy vs switching in this scenario is not well defined. The aim of this study are to report real-world prevalence of symptomatic and endoscopic/radiologic discordance and patient and provider preferences regarding stay or switch advanced therapy in this setting. In the QUOTIENT trial, we performed screening exercises to estimate the prevalence of symptomatic and endoscopic/radiologic discordance using detailed screening logs for eligible patients. Sites completed screening exercises to identify what proportion of patients are eligible to participate in the QUOTIENT trial and willingness to participate. A total of 761 patients were screened for QUOTIENT with complete data. Of patients in corticosteroid-free symptomatic remission on an advanced therapy, 12% had moderate-to-severe endoscopic inflammation. The most common reason for declining to participate was patients’ preference to stay on current advanced therapy (39%). Only 11% preferred switching to advanced therapy as a reason to decline participation. Among patients with IBD who have achieved corticosteroid-free symptomatic remission on advanced therapies, real-world rates of achieving endoscopic remission or mild endoscopic activity are significantly higher than suggested by clinical trials. We observed a strong patient preference to stay on their current advanced therapy, rather than switching to an alternative agent, which contrasts with the providers’ framework for treat-to-target.
- Open Access
- 30 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00942
Treat-to-Target Monitoring Adherence and Rates of Healthcare Utilization in Patients With Inflammatory Bowel Disease in a Regional Healthcare System
INTRODUCTION: The aim of treat-to-target (T2T) algorithms in inflammatory bowel disease was to maximize the benefit of medical therapies by establishing a framework for disease activity assessment to guide therapeutic decisions. There are limited data on adoption rates of T2T monitoring in real-world practice. We aimed to describe rates of T2T monitoring, predictors of completion, and associations with clinical outcomes. METHODS: A retrospective cohort study was conducted from 2015 to 2021 of individuals with inflammatory bowel disease starting new biologic or small molecule therapy within a multistate healthcare system. The completion of biochemical monitoring including fecal calprotectin or C-reactive protein and structural monitoring including endoscopy or enterography, or both, was assessed between 3 and 6 months and 6 and 12 months, respectively. Healthcare utilization (HCU), defined as emergency department visits, hospitalizations, prednisone prescriptions, or abdominal surgery within 2 years, was also assessed. RESULTS: A total of 823 patients were included in the cohort, and 127 (15.4%) completed some form of T2T monitoring. Twenty-two patients (2.7%) completed both biochemical and structural monitoring. The completion of T2T was not associated with lower HCU. The completion of only biochemical T2T, but not structural or both biochemical and structural T2T, was associated with decreased 12-month medication persistence (hazard ratio 0.36, 95% confidence interval 0.17–0.75). The completion of just structural T2T (hazard ratio 1.59, 95% confidence interval 1.05–2.39) was associated with higher HCU. DISCUSSION: In this retrospective cohort of individuals initiating new therapy, the rates of T2T monitoring were low. The completion of all T2T was not associated with lower HCU. The completion of only biochemical T2T monitoring was associated with lower 12-month medication persistence and only structural T2T with higher HCU.
- 30 October 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 17 (1) , e00942
Open AccessTreat-to-Target Monitoring Adherence and Rates of Healthcare Utilization in Patients With Inflammatory Bowel Disease in a Regional Healthcare System
INTRODUCTION: The aim of treat-to-target (T2T) algorithms in inflammatory bowel disease was to maximize the benefit of medical therapies by establishing a framework for disease activity assessment to guide therapeutic decisions. There are limited data on adoption rates of T2T monitoring in real-world practice. We aimed to describe rates of T2T monitoring, predictors of completion, and associations with clinical outcomes. METHODS: A retrospective cohort study was conducted from 2015 to 2021 of individuals with inflammatory bowel disease starting new biologic or small molecule therapy within a multistate healthcare system. The completion of biochemical monitoring including fecal calprotectin or C-reactive protein and structural monitoring including endoscopy or enterography, or both, was assessed between 3 and 6 months and 6 and 12 months, respectively. Healthcare utilization (HCU), defined as emergency department visits, hospitalizations, prednisone prescriptions, or abdominal surgery within 2 years, was also assessed. RESULTS: A total of 823 patients were included in the cohort, and 127 (15.4%) completed some form of T2T monitoring. Twenty-two patients (2.7%) completed both biochemical and structural monitoring. The completion of T2T was not associated with lower HCU. The completion of only biochemical T2T, but not structural or both biochemical and structural T2T, was associated with decreased 12-month medication persistence (hazard ratio 0.36, 95% confidence interval 0.17–0.75). The completion of just structural T2T (hazard ratio 1.59, 95% confidence interval 1.05–2.39) was associated with higher HCU. DISCUSSION: In this retrospective cohort of individuals initiating new therapy, the rates of T2T monitoring were low. The completion of all T2T was not associated with lower HCU. The completion of only biochemical T2T monitoring was associated with lower 12-month medication persistence and only structural T2T with higher HCU.
- 4 March 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3) , otaf012
Anemia in Inflammatory Bowel Disease: Practice Patterns and Clinical Outcomes in a Large National Veterans Cohort
Background: Anemia is a common complication of inflammatory bowel disease (IBD), impacting patient quality of life and clinical outcomes. This study examines anemia management practices and clinical outcomes in a national cohort of veterans with IBD. Methods: A retrospective cohort study of 89,687 veterans with IBD from 2000 to 2017 was conducted using Veterans Health Administration data. We assessed anemia screening, iron store assessments, and iron therapy. Primary outcomes included anemia resolution within 12 months. Secondary outcomes included IBD-related hospitalizations, steroid use, and surgery within five years. Multivariate logistic regression models assessed associations between patient characteristics and clinical outcomes. Results: Among 89,687 VA patients with IBD, 56% experienced anemia, but only 36% received iron testing. Only 23% of patients with iron deficiency received iron therapy within 6 months. Hemoglobin normalization occurred in 19% within a year. IBD patients with comorbidities had lower resolution rates (1-2 comorbidities: OR 0.89). Over five years, 30% were hospitalized, with lower rates for non-smokers (OR 0.81) and higher for those with comorbidities (OR 1.10) or on biologics (OR 1.91). Steroid use was 17.5%, higher in those with comorbidities (OR 1.20) or on biologics (OR 4.11), and lower in Black patients (OR 0.78). Only 2% had surgery, less common among Black patients (OR 0.69) and non-smokers (OR 0.72). Conclusions: Anemia is underdiagnosed and undertreated in veterans with IBD, leading to poor clinical outcomes. Enhanced screening and treatment protocols are essential to improve anemia resolution rates and reduce IBD-related complications.
- 4 March 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3) , otaf012
Anemia in Inflammatory Bowel Disease: Practice Patterns and Clinical Outcomes in a Large National Veterans Cohort
Background: Anemia is a common complication of inflammatory bowel disease (IBD), impacting patient quality of life and clinical outcomes. This study examines anemia management practices and clinical outcomes in a national cohort of veterans with IBD. Methods: A retrospective cohort study of 89,687 veterans with IBD from 2000 to 2017 was conducted using Veterans Health Administration data. We assessed anemia screening, iron store assessments, and iron therapy. Primary outcomes included anemia resolution within 12 months. Secondary outcomes included IBD-related hospitalizations, steroid use, and surgery within five years. Multivariate logistic regression models assessed associations between patient characteristics and clinical outcomes. Results: Among 89,687 VA patients with IBD, 56% experienced anemia, but only 36% received iron testing. Only 23% of patients with iron deficiency received iron therapy within 6 months. Hemoglobin normalization occurred in 19% within a year. IBD patients with comorbidities had lower resolution rates (1-2 comorbidities: OR 0.89). Over five years, 30% were hospitalized, with lower rates for non-smokers (OR 0.81) and higher for those with comorbidities (OR 1.10) or on biologics (OR 1.91). Steroid use was 17.5%, higher in those with comorbidities (OR 1.20) or on biologics (OR 4.11), and lower in Black patients (OR 0.78). Only 2% had surgery, less common among Black patients (OR 0.69) and non-smokers (OR 0.72). Conclusions: Anemia is underdiagnosed and undertreated in veterans with IBD, leading to poor clinical outcomes. Enhanced screening and treatment protocols are essential to improve anemia resolution rates and reduce IBD-related complications.
- Open Access
- 14 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (3) , 386-395
The Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable
- 14 August 2024
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 23 (3) , 386-395
Open AccessThe Cost of Inflammatory Bowel Disease Care: How to Make it Sustainable
- 29 April 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (10) , 2130-2133
Legalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis
INTRODUCTION: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain. METHODS: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without. RESULTS: We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval −13.02 to 13.70, P = 0.96). DISCUSSION: Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.
- 29 April 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (10) , 2130-2133
Legalization of Cannabis Does Not Reduce Opioid Prescribing in Patients With Inflammatory Bowel Disease: A Difference-in-Difference Analysis
INTRODUCTION: Cannabis may provide inflammatory bowel disease (IBD) patients with an alternative to opioids for pain. METHODS: We conducted a difference-in-difference analysis using MarketScan. Changes over time in rates of opioid prescribing were compared in states with legalized cannabis to those without. RESULTS: We identified 6,240 patients with IBD in states with legalized cannabis and 79,272 patients with IBD in states without legalized cannabis. The rate of opioid prescribing decreased over time in both groups and were not significantly different (attributed differential = 0.34, confidence interval −13.02 to 13.70, P = 0.96). DISCUSSION: Opioid prescribing decreased from 2009 to 2016 among patients with IBD in both states with legalized and state without legalized cannabis, similar to what has been observed nationally across a variety of diseases. Cannabis legalization was not associated with a lower rate of opioid prescribing for patients with IBD.
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1788 PATTERNS OF STEROID USE AMONG A REAL-WORLD NATIONAL COHORT VETERANS WITH INFLAMMATORY BOWEL DISEASE ON MAINTENANCE INFLIXIMAB
- 6 July 2023
- Published by Elsevier in Gastroenterology
- Vol. 164 (6)
Tu1788 PATTERNS OF STEROID USE AMONG A REAL-WORLD NATIONAL COHORT VETERANS WITH INFLAMMATORY BOWEL DISEASE ON MAINTENANCE INFLIXIMAB
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
976: THE IMPACT OF CANNABIS LEGALIZATION ON OPIOIDS IN PATIENTS WITH IBD: A DIFFERENCE-IN-DIFFERENCE ANALYSIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
976: THE IMPACT OF CANNABIS LEGALIZATION ON OPIOIDS IN PATIENTS WITH IBD: A DIFFERENCE-IN-DIFFERENCE ANALYSIS
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1492: ANEMIA TREATMENT PATTERNS AND OUTCOMES AMONG A NATIONAL COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Mo1492: ANEMIA TREATMENT PATTERNS AND OUTCOMES AMONG A NATIONAL COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1574: LOSS OF RESPONSE AND ADVERSE EVENTS TO INFLIXIMAB BY RACE IN A NATIONAL COHORT OF VETERANS WITH INFLAMMATROY BOWEL DISEASE
- 16 June 2022
- Published by Elsevier in Gastroenterology
- Vol. 162 (7)
Su1574: LOSS OF RESPONSE AND ADVERSE EVENTS TO INFLIXIMAB BY RACE IN A NATIONAL COHORT OF VETERANS WITH INFLAMMATROY BOWEL DISEASE
- 28 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (12) , 2848-2857.e2
Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease
- 28 February 2022
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (12) , 2848-2857.e2
Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease